Nautilus Biotechnology Reports First Quarter 2024 Financial Results
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.
西雅图,2024年4月30日(环球新闻专线)——开创单分子蛋白质组分析平台的公司鹦鹉螺生物技术有限公司(纳斯达克股票代码:NAUT;或 “Nautilus”)今天公布了截至2024年3月31日的第一季度财务业绩。
"We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus. "We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see meaningful gains along each of those dimensions. We are clear-eyed about what work remains to be done and confident that we have a foundational understanding of what is required to establish a new gold standard for the creation and comprehensive analysis of high-value proteomic data."
诺第留斯首席执行官苏哈尔·帕特尔表示:“我们在第一季度继续在实现核心发展目标方面取得稳步进展。”“我们仍然非常专注于提高我们的消耗品、化验方法、仪器和软件的规模、稳定性和可重复性,并继续看到在这些方面取得有意义的进展。我们清楚地知道还有哪些工作要做,并相信我们对建立创建和全面分析高价值蛋白质组数据的新金标准所需的条件有了基本的了解。”
First Quarter 2024 Financial Results
2024 年第一季度财务业绩
Operating expenses were $21.6 million for the first quarter of 2024, a $3.5 million or 20% increase from $18.1 million for the corresponding prior year period. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.
2024年第一季度的运营支出为2,160万美元,较去年同期的1,810万美元增长了350万美元,增长了20%。运营开支的增加主要是由员工人数的增加所推动的,以支持我们产品的持续开发。
Net loss was $18.7 million for the first quarter of 2024, as compared to a net loss of $15.0 million for the corresponding prior year period.
2024年第一季度的净亏损为1,870万美元,而去年同期的净亏损为1,500万美元。
Cash, cash equivalents, and investments were $247.7 million as of March 31, 2024.
截至2024年3月31日,现金、现金等价物和投资为2.477亿美元。
Webcast and Conference Call Information
网络直播和电话会议信息
Nautilus will host a conference call to discuss the first quarter 2024 financial results, business developments and outlook before market open on Wednesday, April 30, 2024 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.
Nautilus将在太平洋时间2024年4月30日星期三上午5点30分/美国东部时间上午8点30分开盘前举行电话会议,讨论2024年第一季度的财务业绩、业务发展和前景。网络直播的直播音频将在公司网站的 “投资者” 部分提供,网址为: www.nautilus.bio。
About Nautilus Biotechnology, Inc.
关于鹦鹉螺生物技术有限公司
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Nautilus是一家处于开发阶段的生命科学公司,其公司总部位于华盛顿州西雅图,研发总部位于加利福尼亚州的圣卡洛斯,致力于开发一种用于量化和解锁蛋白质组复杂性的平台技术。Nautilus的使命是通过普及蛋白质组并实现人类健康和医学领域的根本进步来改变蛋白质组学领域。要了解有关 Nautilus 的更多信息,请访问 www.nautilus.bio
Special Note Regarding Forward-Looking Statements
关于前瞻性陈述的特别说明
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus' expectations regarding the company's business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the development required for and the timing of the launch of Nautilus' product platform and full commercial availability, the functionality and performance of Nautilus' product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus' products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus' assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus' product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus' scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption "Risk Factors" in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended March 31, 2024 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
本新闻稿包含联邦证券法所指的前瞻性陈述。本新闻稿中的前瞻性陈述包括但不限于关于Nautilus对公司业务运营、财务业绩和经营业绩的预期的陈述;对任何收入时机或预测的预期;对Nautilus产品平台和全面商业可用性所需的开发和发布时间的预期;Nautilus产品平台的功能和性能;其对提供蛋白质组准入的潜在影响;制药开发和药物发现,扩大研究视野,促进科学探索和发现,以及新兴蛋白质组学技术的当前和未来能力和局限性。这些陈述基于有关Nautilus产品开发、目标市场以及其他当前和新兴蛋白质组学技术的众多假设,涉及重大风险、不确定性和其他因素,这些因素可能导致实际结果与这些前瞻性陈述所表达或暗示的信息存在重大差异。可能对Nautilus假设的准确性及其实现本新闻稿中提出的前瞻性陈述的能力产生重大影响的风险和不确定性包括(但不限于)以下内容:Nautilus的产品平台尚未上市,仍有待重大科学和技术发展,这本质上具有挑战性且难以预测,特别是对于Nautilus正在开发的产品等高度新颖和复杂的产品。即使我们的开发工作取得了成功,我们的产品平台也需要对其在生命科学研究中的功能和实用性进行实质性验证。在Nautilus的科学和技术开发以及相关的产品验证和商业化过程中,由于意想不到的事件,我们可能会遇到实质性的延迟。我们无法对我们的开发、合作和商业化计划的结果或其相关时间表提供任何担保或保证。要更详细地描述Nautilus及其开发工作面临的其他风险和不确定性,投资者应参考我们的10-K表年度报告、截至2024年3月31日的季度提交的10-Q表季度报告以及我们向美国证券交易委员会提交的其他文件中 “风险因素” 标题下的信息。本新闻稿中的前瞻性陈述截至本新闻稿发布之日。除非适用法律另有要求,否则,Nautilus不承担更新任何前瞻性陈述的责任。因此,在本新闻稿发布之日之后的任何日期,您都不应依赖这些前瞻性陈述来代表我们的观点。
Disclosure Information
披露信息
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Nautilus使用向美国证券交易委员会提交的文件、其网站(www.nautilus.bio)、新闻稿、公开电话会议、公开网络直播及其社交媒体账户作为披露重要非公开信息和遵守FD法规的手段。因此,Nautilus鼓励投资者、媒体和其他对Nautilus感兴趣的人审查其在这些地方公开的信息,因为此类信息可能被视为重要信息。
Media Contact
press@nautilus.bio
媒体联系人
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
投资者联系人
investorrelations@nautilus.bio
Nautilus Biotechnology, Inc. Condensed Consolidated Balance Sheets As of March 31, 2024 and December 31, 2023 (Unaudited) | |||||||
(in thousands, except share and per share amounts) | March 31, 2024 | December 31, 2023 | |||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 25,729 | $ | 19,397 | |||
Short-term investments | 155,637 | 154,021 | |||||
Prepaid expenses and other current assets | 3,728 | 3,419 | |||||
Total current assets | 185,094 | 176,837 | |||||
Property and equipment, net | 4,525 | 4,267 | |||||
Operating lease right-of-use assets | 31,559 | 32,634 | |||||
Long-term investments | 66,292 | 90,647 | |||||
Other long-term assets | 1,180 | 1,180 | |||||
Total assets | $ | 288,650 | $ | 305,565 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,860 | $ | 1,639 | |||
Accrued expenses and other liabilities | 3,677 | 3,945 | |||||
Current portion of operating lease liabilities | 3,675 | 3,538 | |||||
Total current liabilities | 9,212 | 9,122 | |||||
Operating lease liabilities, net of current portion | 29,946 | 31,090 | |||||
Total liabilities | 39,158 | 40,212 | |||||
Stockholders' equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 13 | 13 | |||||
Additional paid-in capital | 471,193 | 467,834 | |||||
Accumulated other comprehensive income (loss) | (745) | (255) | |||||
Accumulated deficit | (220,969) | (202,239) | |||||
Total stockholders' equity | 249,492 | 265,353 | |||||
Total liabilities and stockholders' equity | $ | 288,650 | $ | 305,565 |
鹦鹉螺生物技术有限公司 简明合并资产负债表 截至 2024 年 3 月 31 日和 2023 年 12 月 31 日(未经审计) | |||||||
(以千计,股票和每股金额除外) | 2024年3月31日 | 2023年12月31日 | |||||
资产 | |||||||
流动资产: | |||||||
现金和现金等价物 | $ | 25,729 | $ | 19,397 | |||
短期投资 | 155,637 | 154,021 | |||||
预付费用和其他流动资产 | 3,728 | 3,419 | |||||
流动资产总额 | 185,094 | 176,837 | |||||
财产和设备,净额 | 4,525 | 4,267 | |||||
经营租赁使用权资产 | 31,559 | 32,634 | |||||
长期投资 | 66,292 | 90,647 | |||||
其他长期资产 | 1,180 | 1,180 | |||||
总资产 | $ | 288,650 | $ | 305,565 | |||
负债和股东权益 | |||||||
流动负债: | |||||||
应付账款 | $ | 1,860 | $ | 1,639 | |||
应计费用和其他负债 | 3,677 | 3,945 | |||||
经营租赁负债的流动部分 | 3,675 | 3,538 | |||||
流动负债总额 | 9,212 | 9,122 | |||||
经营租赁负债,扣除流动部分 | 29,946 | 31,090 | |||||
负债总额 | 39,158 | 40,212 | |||||
股东权益: | |||||||
优先股 | — | — | |||||
普通股 | 13 | 13 | |||||
额外的实收资本 | 471,193 | 467,834 | |||||
累计其他综合收益(亏损) | (745) | (255) | |||||
累计赤字 | (220,969) | (202,239) | |||||
股东权益总额 | 249,492 | 265,353 | |||||
负债和股东权益总额 | $ | 288,650 | $ | 305,565 |
Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2024 and 2023 (Unaudited) | |||||||
Three Months Ended March 31, | |||||||
(in thousands, except share and per share data) | 2024 | 2023 | |||||
Operating expenses | |||||||
Research and development | $ | 12,930 | $ | 10,877 | |||
General and administrative | 8,677 | 7,183 | |||||
Total operating expenses | 21,607 | 18,060 | |||||
Other income (expense) | |||||||
Interest income | 2,877 | 3,098 | |||||
Other expense | — | (3) | |||||
Total other income | $ | 2,877 | $ | 3,095 | |||
Net loss | $ | (18,730) | $ | (14,965) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.15) | $ | (0.12) | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 125,135,451 | 124,590,351 |
鹦鹉螺生物技术有限公司 简明合并运营报表 截至2024年3月31日和2023年3月31日的三个月(未经审计) | |||||||
截至3月31日的三个月 | |||||||
(以千计,股票和每股数据除外) | 2024 | 2023 | |||||
运营费用 | |||||||
研究和开发 | $ | 12,930 | $ | 10,877 | |||
一般和行政 | 8,677 | 7,183 | |||||
运营费用总额 | 21,607 | 18,060 | |||||
其他收入(支出) | |||||||
利息收入 | 2877 | 3,098 | |||||
其他费用 | — | (3) | |||||
其他收入总额 | $ | 2877 | $ | 3,095 | |||
净亏损 | $ | (18,730) | $ | (14,965) | |||
归属于普通股股东的每股净亏损,基本亏损和摊薄后 | $ | (0.15) | $ | (0.12) | |||
用于计算归属于普通股股东的每股净亏损的加权平均股数,基本和摊薄后 | 125,135,451 | 124,590,351 |
Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Cash Flows Three Months Ended March 31, 2024 and 2023 (Unaudited) | |||||||
Three Months Ended March 31, | |||||||
(in thousands) | 2024 | 2023 | |||||
Cash flows from operating activities | |||||||
Net loss | $ | (18,730) | $ | (14,965) | |||
Adjustments to reconcile net loss to net cash used in operating activities | |||||||
Stock-based compensation expense | 3,114 | 2,860 | |||||
Amortization of operating lease right-of-use assets | 1,075 | 786 | |||||
Depreciation | 516 | 385 | |||||
Amortization (accretion) of premium (discount) on securities, net | (751) | (669) | |||||
Changes in operating assets and liabilities: | |||||||
Prepaid expenses and other assets | (309) | (513) | |||||
Accounts payable | 94 | 53 | |||||
Accrued expenses and other liabilities | (268) | 65 | |||||
Operating lease liabilities | (1,007) | (526) | |||||
Net cash used in operating activities | (16,266) | (12,524) | |||||
Cash flows from investing activities | |||||||
Proceeds from maturities of securities | 23,000 | 14,249 | |||||
Purchases of securities | — | (27,052) | |||||
Purchases of property and equipment | (647) | (692) | |||||
Net cash provided by (used in) investing activities | 22,353 | (13,495) | |||||
Cash flows from financing activities | |||||||
Proceeds from exercise of stock options | 245 | 1 | |||||
Net cash provided by financing activities | 245 | 1 | |||||
Net increase (decrease) in cash, cash equivalents and restricted cash | 6,332 | (26,018) | |||||
Cash, cash equivalents and restricted cash at beginning of period | 20,399 | 115,477 | |||||
Cash, cash equivalents and restricted cash at end of period | $ | 26,731 | $ | 89,459 |
鹦鹉螺生物技术有限公司 简明合并现金流量表 截至2024年3月31日和2023年3月31日的三个月(未经审计) | |||||||
截至3月31日的三个月 | |||||||
(以千计) | 2024 | 2023 | |||||
来自经营活动的现金流 | |||||||
净亏损 | $ | (18,730) | $ | (14,965) | |||
为将净亏损与经营活动中使用的净现金进行对账而进行的调整 | |||||||
股票薪酬支出 | 3,114 | 2,860 | |||||
经营租赁使用权资产的摊销 | 1,075 | 786 | |||||
折旧 | 516 | 385 | |||||
证券溢价(折扣)的摊销(增加),净额 | (751) | (669) | |||||
运营资产和负债的变化: | |||||||
预付费用和其他资产 | (309) | (513) | |||||
应付账款 | 94 | 53 | |||||
应计费用和其他负债 | (268) | 65 | |||||
经营租赁负债 | (1,007) | (526) | |||||
用于经营活动的净现金 | (16,266) | (12,524) | |||||
来自投资活动的现金流 | |||||||
证券到期的收益 | 23,000 | 14,249 | |||||
购买证券 | — | (27,052) | |||||
购买财产和设备 | (647) | (692) | |||||
由(用于)投资活动提供的净现金 | 22,353 | (13,495) | |||||
来自融资活动的现金流 | |||||||
行使股票期权的收益 | 245 | 1 | |||||
融资活动提供的净现金 | 245 | 1 | |||||
现金、现金等价物和限制性现金的净增加(减少) | 6,332 | (26,018) | |||||
期初现金、现金等价物和限制性现金 | 20,399 | 115,477 | |||||
期末现金、现金等价物和限制性现金 | $ | 26,731 | $ | 89,459 |
译文内容由第三方软件翻译。